



Atty. Dkt. No. 355908-2500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON et al.

Title: INFLAMMATORY CYTOKINE
SECRETION INHIBITION

Appl. No.: 10/002,634

Filing Date: December 5, 2001


Examiner: M. Belyavskyi

Art Unit: 1644

CERTIFICATE OF EXPRESS MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 512614906 US June 28, 2004
(Express Mail Label Number) (Date of Deposit)

Rene Campos
(Printed Name)


(Signature)

CLAIM FOR CONVENTION PRIORITY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The benefit of the filing dates of the following prior foreign applications filed in the following foreign country is hereby requested, and the right of priority provided in 35 U.S.C. § 119 is hereby claimed.

In support of this claim, filed herewith are certified copies of said original foreign applications:

- CANADA Patent Application No. 2,327,628 filed 12/5/2000.
- CANADA Patent Application No. 2,327,631 filed 12/5/2000.

Respectfully submitted,

Date 6 -28 -04

By Gerald F. Swiss

Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 856-7513
Facsimile: (650) 856-3710



Office de la propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An Agency of
Industry Canada


Bureau canadien
des brevets
Certification

La présente atteste que les documents
ci-joints, dont la liste figure ci-dessous,
sont des copies authentiques des docu-
ments déposés au Bureau des brevets.

Canadian Patent
Office
Certification

This is to certify that the documents
attached hereto and identified below are
true copies of the documents on file in
the Patent Office.

Specification and Drawings, as originally filed, with Application for Patent Serial No:
2,327,631, on December 5, 2000, by **VASOGEN IRELAND LIMITED**, for
“Inflammatory Cytokine Secretion Inhibition”



Agent certificatuer/Certifying Officer

April 16, 2004

Date

Canada

(CIPO 68)
04-09-02

O P I C  C I P O

ABSTRACT OF THE DISCLOSURE

A process of decreasing the expression of one or more of the inflammatory cytokines IFN- γ , IL-6 and IL-12 from cells in a mammalian patient, comprises administering to the patient an effective amount of stressed mammalian blood cells, said stressed cells having been extracorporeally subjected to at least one stressor selected from oxidative stress and ultraviolet radiation.

INFLAMMATORY CYTOKINE SECRETION INHIBITION

Field of the Invention

This invention relates to treatment of biological cells and immune system modulation. More specifically, it relates to treatment of cells of the mammalian immune system to alter the cytokine profiles of certain types of constituent cells, and therapeutic applications of such treatments.

Background of the Invention

The mammalian immune system comprises lymphocytes (one type of white blood cell), the major components of which are B cells, which mature within the bone marrow, and T cells which migrate from the bone marrow to mature in the thymus gland. B cells react to antigens to proliferate and differentiate into memory B cells and effector B cells to generate and express antibodies specific to the antigen, to combat it. T cells have T cell receptors which recognize antigen associated with MHC molecules on a cell, to differentiate into memory T cells and various types of effector T cells. The T cell population is made up of T-helper (T_H) cells and T-cytotoxic (T_c) cells, distinguished from one another by the presence of surface membrane glycoprotein CD4 on T_H cells and surface membrane glycoprotein CD8 on T_c cells. Activation of a T_H cell can cause it to secrete various growth factors (cytokines). Different types of T_H cells secrete different cytokines. These cytokines play key roles in the immune response, including autoimmune responses.

One type of T_H cell, known as T_{H1} , expresses cytokines which, in excessive amounts, can cause inflammation in the mammalian body. Examples of such inflammatory cytokines include interferon- γ (IFN- γ), interleukin-6 (IL-6) and interleukin-12 (IL-12). When the body produces inappropriately large amounts of inflammatory cytokines, significantly more than endogenous levels found in the corresponding non-diseased tissue of healthy individuals, either through over-activation of T_{H1} cells, activation of excessive numbers of T_{H1} cells, or a switch of

- 2 -

other types of T cells to the T_H1 type to create excessive numbers of cytokines expressing T_H1 cells, an inflammatory disorder can manifest itself in a patient.

Summary of the Invention

The present invention provides a process whereby expression of inflammatory cytokines including IFN- γ , IL-6 and IL-12, either individually or in combination, is reduced in a mammalian patient body. The process involves introducing into the patient blood cells which have been extracorporeally stressed by subjection to an oxidative stress and/or ultraviolet radiation. On introduction of these stressed blood cells, there is a reduction in the expression of one or more of these inflammatory cytokines, either by down regulating T_H1 cells, or perhaps by decreasing the population of T_H1 cells, e.g. by causing a switch of T cells from T_H1 to T_H2. Whatever the precise mechanism of action, the result is a significant and measurable decrease in these inflammatory cytokines in the patient's system. Accordingly, the process of the invention is useful in the medical treatment of patients suffering from, prone to or at risk of contracting a disorder associated with excessive amounts of one or more of the inflammatory cytokines IFN- γ , IL-6 and IL-12 (e.g. chronic fatigue syndrome - see Cannon et.al., "Acute phase responses and cytokine secretion in chronic fatigue syndrome", *J.Clin. Immunol.* 1999 Nov; 19(6): 414-21; and Gupta, S. et.al., *Int. J. Mol. Med.*, 1999 Feb; 3(2): 209-13).

Thus according to the present invention, there is provided a process of decreasing the expression of one or more of the inflammatory cytokines IFN- γ , IL-6 and IL-12 from cells in a mammalian patient, which comprises administering to the patient an effective amount of stressed mammalian blood cells, said stressed cells having been extracorporeally subjected to at least one stressor selected from oxidative stress and ultraviolet radiation.

There is further provided a method for treating an inflammatory disease condition in a patient mediated by inflammatory cytokine production, which method comprises administering to the patient an effective amount of

- 3 -

stressed mammalian blood cells wherein said stressed mammalian blood cells have been extracorporeally subjected to at least one stressor selected from oxidative conditions and ultraviolet radiation.

Brief Reference to the Drawings

The accompanying Figures 1 and 2 are graphical presentations of the results of the experiment reported below as a specific Example.

Description of the Preferred Embodiments

A preferred embodiment of the invention is a process of decreasing the expression of IL-6 and IL-12 from cells in a mammalian patient, which comprises administering to the patient an effective amount of stressed mammalian blood cells, said stressed cells having been extracorporeally subjected to at least one stressor selected from oxidative stress and ultraviolet radiation. Such a process is useful in treating medical disorders associated with excess expressions or excess presence of cytokine IL-6 and/or cytokine IL-12. A preferred application of the process of the present invention is in the treatment of disorders other than graft versus host disease, and other than autoimmune diseases such as rheumatoid arthritis, psoriasis, scleroderma, lupus, diabetes mellitus, organ rejection, miscarriage, multiple sclerosis, inflammatory bowel disease and atherosclerosis, and other than contact hypersensitivity disorders.

A particularly preferred embodiment is a process of decreasing IL-6 expression from cells in a mammalian patient which comprises administering to the patient an effective amount of stressed mammalian blood cells, said stressed cells having been extracorporeally subjected to at least one stressor selected from oxidative stress and ultraviolet radiation. This process is particularly useful in alleviation of disorders such as chronic fatigue syndrome.

The source of the stressed blood cells for use in the present invention is preferably the patient's own blood, i.e. an aliquot of autologous blood.

- 4 -

The terms "aliquot", "aliquot of blood" or similar terms used herein include whole blood, separated cellular fractions of the blood including platelets, separated non-cellular fractions of the blood including plasma, plasma components and combinations thereof. Preferably, in human patients, the volume of the aliquot is up to about 400 ml, preferably from about 0.1 to about 100 ml, more preferably from about 1 to about 15 ml, even more preferably from about 8 to about 12 ml, and most preferably about 10 ml. The effect of the stressor or the combination of stressors is to modify the blood, and/or the cellular or non-cellular fractions thereof, contained in the aliquot. The modified aliquot is then re-introduced into the subject's body by any suitable method, most preferably Intramuscular injection, but also including Subcutaneous injection, Intraperitoneal Injection, Intra-arterial injection, Intravenous injection and oral administration, following which it causes decrease in the expression of one or more of the inflammatory cytokines INF- γ , IL-6 and IL-12.

According to a preferred process of the present invention, an aliquot of blood is extracted from a mammalian subject, preferably a human, and the aliquot of blood is treated ex vivo, simultaneously or sequentially, with the aforementioned stressors. Then it is injected back into the same subject. Preferably a combination of both of the aforementioned stressors is used.

Preferably also, the aliquot of blood is in addition subjected to mechanical stress. Such mechanical stress is suitably that applied to the aliquot of blood by extraction of the blood aliquot through a conventional blood extraction needle, or a substantially equivalent mechanical stress, applied shortly before the other chosen stressors are applied to the blood aliquot. This mechanical stress may be supplemented by the mechanical stress exerted on the blood aliquot by bubbling gases through it, such as ozone/oxygen mixtures, as described below. Optionally also, a temperature stressor may be applied to the blood aliquot, simultaneously or sequentially with the other stressors, i.e. a temperature at, above or below body temperature.

- 5 -

The optionally applied temperature stressor either warms the aliquot being treated to a temperature above normal body temperature or cools the aliquot below normal body temperature. The temperature is selected so that the temperature stressor does not cause excessive hemolysis in the blood contained in the aliquot, and so that, when the treated aliquot is injected into a subject, the desired effect will be achieved, without development of significant adverse side effects. Preferably, the temperature stressor is applied so that the temperature of all or a part of the aliquot is up to about 55°C, and more preferably in the range of from about -5°C to about 55°C.

In some preferred embodiments of the invention, the temperature of the aliquot is raised above normal body temperature, such that the mean temperature of the aliquot does not exceed a temperature of about 55°C, more preferably from about 40°C to about 50°C, even more preferably from about 40°C to about 44°C, and most preferably about 42.5 ± 1°C.

In other preferred embodiments, the aliquot is cooled below normal body temperature such that the mean temperature of the aliquot is within the range of from about 4°C to about 36.5°C, more preferably from about 10°C to about 30°C, and even more preferably from about 15°C to about 25°C.

The oxidative environment stressor can be the application to the aliquot of solid, liquid or gaseous oxidizing agents. Preferably, it involves exposing the aliquot to a mixture of medical grade oxygen and ozone gas, most preferably by applying to the aliquot medical grade oxygen gas having ozone as a component therein. The ozone content of the gas stream and the flow rate of the gas stream are preferably selected such that the amount of ozone introduced to the blood aliquot, either on its own or in combination with one of the other stressors, does not give rise to excessive levels of cell damage, without significant adverse side effects.

Suitably, the gas stream has an

- 6 -

ozone content of up to about 300 µg/ml, preferably up to about 100 µg/ml, more preferably about 30 µg/ml, even more preferably up to about 20 µg/ml, particularly preferably from about 10 µg/ml to about 20 µg/ml, and most preferably about 14.5 ± 1.0 µg/ml. The gas stream is suitably supplied to the aliquot at a rate of up to about 2.0 litres/min, preferably up to about 0.5 litres/min, more preferably up to about 0.4 litres/min, even more preferably up to about 0.33 litres/min, and most preferably about 0.24 ± 0.024 litres/min. The lower limit of the flow rate of the gas stream is preferably not lower than 0.01 litres/min, more preferably not lower than 0.1 litres/min, and even more preferably not lower than 0.2 litres/min, all rates at STP.

The ultraviolet light stressor is suitably applied by irradiating the aliquot under treatment from a source of UV light. Preferred UV sources are UV lamps emitting UV-C band wavelengths, i.e. at wavelengths shorter than about 280 nm. Ultraviolet light corresponding to standard UV-A (wavelengths from about 315 to about 400 nm) and UV-B (wavelengths from about 280 to about 315) sources can also be used. As in the case of the oxidative stressor, the UV dose should be selected, on its own or in combination of the other chosen stressor(s), so that excessive amounts of cell damage do not occur, and so that, when the treated aliquot is injected into a subject, the desired effect will be achieved. For example, an appropriate dosage of such UV light, can be obtained from up to eight lamps arranged to be exposed to the sample container holding the aliquot, operated at an intensity to deliver a total UV light energy at 253.7 nm at the surface of the blood of from about 0.025 to about 10 joules/cm², preferably from about 0.1 to about 3.0 joules/cm². Such a treatment, applied in combination with the oxidative environment stressor, provides a modified blood aliquot which is ready for injection into the subject.

It is preferred to subject the aliquot to the oxidative environment stressor, the UV light stressor and the temperature stressor simultaneously, following the subjection of the aliquot to the mechanical stress, e.g. by extraction of the blood from the patient. Thus, the aliquot may be maintained at a predetermined temperature above or below body temperature while the

- 7 -

oxygen/ozone gas mixture is applied thereto and while it is irradiated with ultraviolet light.

The time for which the aliquot is subjected to the stressors is normally within the time range of from about 0.5 minutes up to about 60 minutes. The time depends to some extent upon the chosen combination of stressors. When UV light is used, the intensity of the UV light may affect the preferred time. The chosen temperature level may also affect the preferred time. When oxidative environment in the form of a gaseous mixture of oxygen and ozone applied to the aliquot is chosen as one of the two stressors, the concentration of the oxidizing agent and the rate at which it is supplied to the aliquot may affect the preferred temperature. Some routine experimentation to establish optimum times may be necessary on the part of the operator, once the other stressor levels have been set, such experimentation being well within the skill of the art. Under most stressor conditions, preferred times will be in the approximate range of from about 2 to about 5 minutes, more preferably about 3 minutes. The starting blood temperature, and the rate at which it can be warmed or cooled to a predetermined temperature, tends to vary from subject to subject. Warming is suitably by use of one or more infrared lamps placed adjacent to the aliquot container. Other methods of warming can also be adopted.

As noted, it is preferred to subject the aliquot of blood to a mechanical stressor, as well as the chosen stressor(s) discussed above. Extraction of the blood aliquot from the patient through an injection needle constitutes the most convenient way of obtaining the aliquot for further extracorporeal treatment, and this extraction procedure imparts a suitable mechanical stress to the blood aliquot. The mechanical stressor may be supplemented by subsequent processing, for example the additional mechanical shear stress caused by bubbling as the oxidative stressor is applied.

In the practice of the preferred process of the present invention, the blood aliquot may be treated with the heat, UV light and oxidative environment

- 8 -

stressors using an apparatus of the type described in aforementioned U.S. Patent No. 4,968,483 to Mueller. The aliquot is placed in a suitable, sterile container, which is fitted into the machine. A UV-permeable container is used and the UV lamps are switched on for a fixed period before the other stressor is applied, to allow the output of the UV lamps to stabilize. When a temperature stressor is used combination, the UV lamps are typically on while the temperature of the aliquot is adjusted to the predetermined preferred value, e.g. 42.5 \pm 1°C. Four UV lamps are suitably used, placed around the container.

In the preferred method of the Invention, a mammalian patient under treatment for an IFN- γ mediated disorder, an IL-6 mediated disorder and/or a IL-12 mediated disorder is given one or more courses of treatments, each course of treatment comprising the administration to a mammalian subject of one or more (e.g. one to six or one to twelve) aliquots of mammalian blood modified as discussed above.

For optimum effectiveness of the treatment, it is preferred that no more than one aliquot of modified blood be administered to the subject per day, in one or more injection sites, and that the maximum rest period between any two consecutive aliquots during the course of treatment be no greater than about 21 days. As used herein, the term "rest period" is defined as the number of days between consecutive aliquots or consecutive courses of treatment on which no aliquots of modified blood are administered to the subject.

Therefore, except where aliquots are administered to the subject on consecutive days, a rest period of from 1 to 21 days is provided between any two aliquots during the course of treatment. Moreover, at least one of the rest periods during the course of treatment preferably has a length of about 3 to 15 days.

Although it may be sufficient to administer only one course of treatment as described above to the subject, it may be preferred in some circumstances to administer more than one course of treatment, or to follow the

- 9 -

above-described course of treatment by periodic "booster" treatments, if necessary, to maintain the desired effects of the present invention. For example, it may be preferred to administer booster treatments at intervals of 3 to 4 months following the initial course of treatment, or to administer a second course of treatments to the subject following a rest period of several weeks or months.

The invention is further illustrated and described with reference to the following specific example, comprising animal studies conducted in an approved manner.

EXAMPLE

As a measure of the effect of the process of the present invention on inflammation resulting from T cell secretions, a contact hypersensitivity (CHS) test was used, according to approved animal experimentation procedures, using the method described by Kondo et. al., "Lymphocyte function associated antigen-1 (LFA-1) is required for maximum elicitation of allergic contact dermatitis" Br J.Dermatol. 131:354-359, 1994, with minor variations.. The disclosure thereof is incorporated herein by reference. Briefly, to induce CHS, the abdominal skin of each mouse was shaved and painted with dinitrofluorobenzene DNFB, the sensitizing chemical, using 25 μ l of 0.5% DNFB in 4:1 acetone:olive oil solution. This sensitization was applied to four groups of five Balb/c mice. In addition, a measure of the responsible cytokines was made.

Whole blood was obtained from Balb/c mice, by extraction from a main artery through an injection needle, and treated with an anti-coagulant. An aliquot of this was subjected to the process described herein, to obtain treated blood. The remainder was left untreated, for use in control experiments. Since these mice are genetically identical, the administration of the treated blood to others of the group is equivalent to administration of the treated blood to the donor animal.

- 10 -

To obtain treated blood, the selected aliquot, in a sterile, UV-transmissive container, was treated simultaneously with a gaseous oxygen/ozone mixture and ultraviolet light at elevated temperature using an apparatus as generally described in aforementioned U.S. Patent No. 4,968,483 Mueller et.al. Specifically, 12 ml of citrated blood was transferred to a sterile, low density polyethylene vessel (more specifically, a Vasogen VC7002 Blood Container) for ex vivo treatment with stressors according to the invention. Using an apparatus as described in the aforementioned Mueller patent (more specifically, a Vasogen VC7001 apparatus), the blood was heated to $42.5 \pm 1^\circ\text{C}$ and at that temperature irradiated with UV light principally at a wavelength of 253.7 nm, while oxygen/ozone gas mixture was bubbled through the blood to provide the oxidative environment and to facilitate exposure of the blood to UV. The constitution of the gas mixture was $14.5 \pm 1.0 \mu\text{g}$ ozone/ml, with the remainder of the mixture comprising medical grade oxygen. The gas mixture was bubbled through the aliquot at a rate of $240 \pm 24 \text{ ml/min}$ for a period of 3 minutes.


Of the 4 groups of sensitized mice, the first, control group A-1 received no treatment. The second, control group B-1, was treated with physiological saline, 50 μl . The third, control group C-1, was sham treated, with 50 μl of blood which had been extracted but not treated with the stressors. The fourth, test group D-1, was treated with 50 μl of blood subjected to stressors as described above. Treatments, each involving intramuscular injection of 50 μl of the respective liquid, started on the day of sensitization, and was repeated every day for a total of 6 days. On the same day as the last treatment, but after its administration, the animals were challenged with DNFB, by applying to the ears of each animal 10 μl of 0.2% solution of DNFB. Inflammation due to CHS manifests itself in a swelling of the ears. Ear thickness was measured, 24 hours after challenge, with a Peacock spring-loaded micrometer (Ozaki Co., Tokyo, Japan). The results were expressed as the change (from pre-challenge level) in ear thickness and represent the mean maximal increase at 24 hours after challenge.

Lymph nodes were drained from each of the animals after the

- 11 -

conclusion of the above procedures, and the lymph tissue tested, by standard, known rtPCR technology, for expression of the mRNA of the cytokines IFN- γ , IL-6 and IL-12. This process of testing and analysis followed the procedures described in Kondo, S., et.al., (1996) J.Immunology, p.157;4822. Thus the PCR products were determined by scanning of photonegatives using a laser densitometer, and the densitometric value of the IFN- γ was normalized to that of the housekeeping gene B-actin. The analyses indicated that animals which had received a course of injection of blood subjected to stressors as described had significantly reduced IFN- γ , IL-6 and IL-12 as compared with sham treated animals and controls, as illustrated in the accompanying Figures, in general correlation with the anti-inflammation results.

Cytokine Profile of VAS972



1 - B-actin (VAS972)	4- IFN- γ (VAS972)
2- B-actin (sham)	5 -IFN- γ (sham)
3 - B-actin (control)	6 -IFN- γ (control)

FIGURE 1

BEST AVAILABLE COPY

FROM NIXON VANDERHIE PC (TUE) 12. 5' 00 12:43/ST. 12:31/NO. 4261594651 P. 26
Dec 04 00 04:28p

DERMATOLOGY RESEARCH

(415) 480-5743

p.2

115

Cytokine Profile of IL-6 using VAS972




FIG 2.

BEST AVAILABLE COPY